The primary outcome from a RCT in Crohn’s disease shows biosimilar infliximab is comparable to reference infliximab in terms of efficacy and safety
▲ Remsima booth spot at 2017 ECCO
[Feb 20, 2017] Today at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO), Celltrion presented the primary outcome from its pivotal randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab) in Crohn’s disease. The data indicate that the safety and efficacy of CT-P13 in patients with moderate-to-severe Crohn’s disease (CD) is comparable to those treated with reference infliximab.
The Phase III RCT in 220 patients with CD examined whether CT-P13 is comparable to reference infliximab as determined by the Crohn’s Disease Activity Index (CDAI), a measurement used to quantify the symptoms of CD patients. According to the 6 week and 30 week data, similar clinical remission, CDAI-70 and CDAI-100 response rates were observed in both CT-P13 and reference infliximab treatment groups.
Leading expert Jørgen Jahnsen, Professor of Gastroenterology at the University of Oslo, Norway commented on the study, “This is the first RCT to examine the use of a biosimilar in inflammatory bowel disease. While we already have a wealth of extrapolated and real-world data for CT-P13, gastroenterologists have for some time wanted the reassurance of an RCT and it’s encouraging to see such positive data from Celltrion’s RCT trial.”
Celltrion also presented data from two observational studies. The first study evaluated the efficacy and safety of CT-P13 in 74 paediatric patients with CD (naïve patients: 26, switch patients: 25) or ulcerative colitis (UC) (naïve patients: 16, switch patients: 7). The data show that CT-P13 is effective in both treatment-naïve and switch paediatric patients over 30 weeks and is well-tolerated.
The second study examined 204 CD patients (fistulising CD: 24, CD patients: 180) in South Korea from July 2012-2016. CT-P13 was found to be clinically consistent to reference infliximab and well tolerated up to six months in patients with moderate-to-severe CD and those with fistulising CD.
CT-P13 has delivered significant health savings across Europe
Real-world cost savings associated with the use of CT-P13 across all
indications were studied in five European countries from the beginning of 2015 to the
first half of 2016. According to the data presented at ECCO, total cost savings observed for Germany, Italy, Spain and the UK
amounted to €32.4 million and the
findings suggest that this could allow an additional 5,428
patients a year access to this important biologic
therapy. There were no cost
savings in France, as the price of biosimilar and reference infliximab were the
same, however despite this, use of CT-P13 has gradually increased in this country.